Is doping a problem at the Tour de France? - BikeRadar

What the report says

BikeRadar published an explainer on whether doping remains a problem at the Tour de France, framing the issue through cycling’s long-running reputational damage from the Festina affair and the Lance Armstrong era. The outlet noted that Armstrong’s seven Tour titles from 1999 to 2005 were later removed after he admitted systematic doping, and said that legacy continues to shape how dominant performances are viewed.

The article cited journalist James Witts, author of Dope: How Drugs Changed Sport, who told BikeRadar there have been no Tour scandals on Armstrong’s scale in recent years. BikeRadar highlighted stronger anti-doping systems introduced since then, especially the biological passport, launched in 2008 to monitor riders’ blood values over time, and the Whereabouts system, which requires riders to be available for testing.

BikeRadar also reported that recent nighttime doping controls involving Jonas Vingegaard and Tadej Pogačar reignited debate about how far testing should go. The article stressed that a lack of positive tests does not prove the absence of cheating, pointing to ongoing concerns over EPO micro-dosing, the difficulty of distinguishing banned manipulation from altitude-training effects, limited overnight testing, and the cost of enforcement.

Looking ahead, BikeRadar said emerging science could create new challenges, including drugs developed faster than testing methods can detect, potentially aided by AI. The overall conclusion presented was cautious: professional cycling appears cleaner and better monitored than during its worst scandals, but anti-doping gaps remain and the sport’s history makes skepticism difficult to dispel.